Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer
NCT01143285 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2016-04-25
Summary
Description of active nutritional support: Early and active nutritional support is mainly concerned with maintaining protein and energy intake levels despite chemotherapy. A part-time nutritionist will be assigned to each research centre. She will cover active nutritional support during a one-hour consultation and assist the investigating oncologist in filling out the e-CRF data. A two-day meeting prior to the beginning of the study will enable the standardization of active nutritional support strategy across all research centres:
* The nutritionist will explain the consequences of the side effects of chemotherapy on appetite levels and nutritional status.
* Spontaneous oral intake and eating habits will be assessed based on a qualitative and quantitative 3-day food record.
* Then the nutritionist will explain to patients how to adapt their diet (fortification, portion control etc.) according to personal preferences and dietary habits, appetite fluctuation and side effects.
* A booklet containing an overview of the nutritional counsel, recipe ideas, an example of a daily menu, energy equivalence tables and specific diet and hygiene tips for each possible side effects of chemotherapy will be given to all patients.
* During each consultation, patients will be weighed, appetite and food intake will be evaluated (24-hour record except for prospective 3-day record of V0, V3, V6, V9, V12, V13 and V14 consultations), chemotherapy side effects will be recorded and nutritional counsel will be adapted to each patient's individual situation. In case of decrease in food intake and/or weight loss, a protein- and energy-rich oral supplement will be given.
In both groups, if a patient exhibits signs of malnutrition (weight loss \>5% over a one-month period or \> 10% in total) and/or food intake less than 50% of estimated daily requirements, an oral supplement will be given after approval of the oncologist. If this measure is insufficient, artificial nutrition (enteral or parenteral) will be considered.
Conditions
Interventions
- OTHER
-
Early and active nutritional support.
The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
Sponsors & Collaborators
-
UNICANCER
collaborator OTHER -
Centre Leon Berard
collaborator OTHER -
Centre Val d'Aurelle
collaborator UNKNOWN -
University Hospital, Montpellier
collaborator OTHER -
Assistance Publique Hopitaux De Marseille
collaborator OTHER -
Centre hospitalier de Perpignan
collaborator OTHER -
Institut Sainte Catherine
collaborator OTHER -
Centre Hospitalier Universitaire de Nice
lead OTHER
Principal Investigators
-
Xavier HEBUTERNE, PU-PH · Centre Hospitalier Universitaire de Nice
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2014-12-31
- Completion
- 2016-04-30
Countries
- France
Study Locations
More Related Trials
-
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
NCT02960282 ·Status: TERMINATED
-
3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases
NCT04755907 ·Status: UNKNOWN
-
Chemotherapy With DNA Damaging Agents In Colorectal Cancer
NCT01456923 ·Status: COMPLETED ·Phase: PHASE1
-
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
NCT01307878 ·Status: COMPLETED ·Phase: PHASE3
-
Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer
NCT01129700 ·Status: COMPLETED ·Phase: PHASE2
-
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
NCT03532711 ·Status: COMPLETED
-
Dietary Fiber and Probiotics in Advanced Colorectal Cancer
NCT07194954 ·Status: COMPLETED ·Phase: NA
-
The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study
NCT04567459 ·Status: UNKNOWN ·Phase: NA
-
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
NCT01170299 ·Status: COMPLETED ·Phase: NA
-
Effect of the Use of Symbiotics in Patients With Colon Cancer
NCT04874883 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
NCT05414461 ·Status: COMPLETED ·Phase: PHASE2
-
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
NCT06858956 ·Status: NOT_YET_RECRUITING
-
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429 ·Status: ACTIVE_NOT_RECRUITING
-
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
NCT06778382 ·Status: RECRUITING ·Phase: PHASE2
-
Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas
NCT04566029 ·Status: COMPLETED
-
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
NCT03142282 ·Status: UNKNOWN ·Phase: PHASE2
-
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
NCT07346729 ·Status: COMPLETED
-
Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer
NCT05279612 ·Status: UNKNOWN
-
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
NCT06120127 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer
NCT06879197 ·Status: COMPLETED
-
ePRO for Adjuvant Therapy of Colorectal Adenocarcinoma
NCT04069455 ·Status: UNKNOWN ·Phase: NA
-
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
NCT05914389 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4
NCT02305368 ·Status: COMPLETED
-
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
NCT03125161 ·Status: UNKNOWN ·Phase: PHASE3
-
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
NCT07319364 ·Status: RECRUITING ·Phase: PHASE1